Skip to main content
SpringerLink
Log in

The value of prognostic factors in prostatic cancer

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Several prognostic parameters of prostatic carcinoma needed to help guide treatment in individual patients are discussed.

Tumour volume, nodal and bone metastases, grading, prostate-specific antigen and DNA ploidy have been correlated with prognosis. Recent studies have analysed tumour volume in detail. However, currently there is no single prognostic factor which can predict tumour aggressiveness on an individual patient basis to rationalize decisions.

Multivariate analyses are therefore in progress to determine independent prognostic variables.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allhoff, E. P., de Riese, W., Otto, J. U., Gonnermann, O.: Der DNA-Index in der Prognoseerfassung des Prostatakarzinoms.Urologe [A],30, A 19 (1991).

    Google Scholar 

  2. Anscher, M. S., Prosnitz, L. R.: Multivariate analysis of factors predicting local relapse after radical prostatectomy. Possible indications for postoperative radiotherapy.Int. J. Radiat. Oncol. Biol. Phys., 21, 941 (1991).

    PubMed  CAS  Google Scholar 

  3. Arai, Y., Yoshiki, T., Yoshida, O.: Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.J. Urol., 144, 1415 (1990).

    PubMed  CAS  Google Scholar 

  4. Arai, Y., Yoshiki, T., Yambe, H., Yoshida, O.: Value of prostate-specific antigen measurement in predicting lymph node involvement in prostatic cancer.Urol. Int., 45, 356 (1990).

    PubMed  CAS  Google Scholar 

  5. Armitage, T. G., Cooper, E. H., Newling, D. W. W., Robinson, M. R. G., Appleyard, I.: The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.Br. J. Urol., 62, 584 (1988).

    PubMed  CAS  Google Scholar 

  6. Van Aubel, O. G., Bolt-de Vries, J. M., Blankenstein, M. A.: Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer.Prostate, 12, 191 (1988).

    Article  PubMed  Google Scholar 

  7. Barbiarz, B., Peters-Gee, J. M., Crissman, J. D., Cerny, J. C., Miles, B. J.: DNA quantitation in prostatic adenocarcinoma: A comparison between primary tumor and lymph node metastasis.J. Urol., 145, 215 A (1991).

    Google Scholar 

  8. Barrack, E. R., Brendler, C. B., Walsh, P. C.: Steroid receptor and biochemical profiles in prostatic cancer: Correlation with response to hormonal treatment. Prostate cancer, Part A: Research, endocrine treatment, and histopathology.Prog. Clin. Biol. Res., 243, 79 (1987).

    Google Scholar 

  9. Bartsch, G., Janetschek, G., Daxenbichler, G.: Enzyme and receptor analyses as criteria for hormone responsiveness in the treatment of prostatic cancer—limitations. Prostate cancer, Part A: Research, endocrine treatment, and histopathology.Prog. Clin. Biol. Res., 243, 101 (1987).

    Google Scholar 

  10. Böcking, A., Kiehn, J., Heinzel-Wach, M.: Combined histologic grading in prostatic carcinoma.Cancer, 50, 288 (1982).

    Article  PubMed  Google Scholar 

  11. Brawer, M. K., Lange, P. H.: PSA in the screening, staging and follow-up of early-stage prostate cancer—A review of recent developments.World J. Urol., 7, 7 (1989).

    Article  Google Scholar 

  12. Broders, A. C.: Grading and prostatic application.Arch. Pathol. Lab. Med., 1, 376 (1926).

    Google Scholar 

  13. Buamah, P. P. K., Johnson, P., Skillen, A. W.: Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.Br. J. Urol., 62, 581 (1988).

    Article  PubMed  CAS  Google Scholar 

  14. Dhom, G.: Classification and grading of prostatic carcinoma. Research results.Cancer Res., 60, 14 (1977).

    Google Scholar 

  15. Emrich, L. J., Pirol, R. L., Murphy, G. P., Brady, M. F.: Prognostic factors in patients with advanced stage prostate cancer.Cancer Res., 45, 5173 (1985).

    PubMed  CAS  Google Scholar 

  16. Fentie, D. D., Lakey, W. H., McBlain, W. A.: Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma.J. Urol., 135, 167 (1986).

    PubMed  CAS  Google Scholar 

  17. Frank, L. M.: Latent carcinoma of the prostate.J. Pathol. Bacteriol., 68, 603 (1954).

    Article  Google Scholar 

  18. Gervasi, L. A., Mata, J., Easley, J. D.: Prognostic significance of lymph nodal metastases in prostate cancer.J. Urol., 142, 332 (1989).

    PubMed  CAS  Google Scholar 

  19. Gleason, D. F.: Classification of prostatic carcinoma.Cancer Chemother. Rep., 50, 125 (1966).

    PubMed  CAS  Google Scholar 

  20. Gorelic, S., Lamm, D. L., Ramzy, I.: Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation of prognostic significance of receptor measurements for survival of advanced cancer patients.Cancer, 60, 211 (1987).

    Article  PubMed  CAS  Google Scholar 

  21. Hammerer, P., Huland, H.: Zur Diagnostik des lokalisierten Prostatakarzinoms. Screening und präoperatives Staging.Urologe [A],30, 378 (1991).

    CAS  Google Scholar 

  22. Haugen, O. A., Mjdnerod, O.: DNA-ploidy as prognostic factor in prostatic carcinoma.Int. J. Cancer. 45, 224 (1990).

    Article  PubMed  CAS  Google Scholar 

  23. Houland, B.: Latent prostatic cancer in a consecutive autopsy series.Scand. J. Urol. Nephrol., 14, 29 (1980).

    Google Scholar 

  24. Helpap, A., Böcking, A., Dhom, G., Faul, P., Kastendieck, H., Leistenschneider, W., Müller, H. A.: Klassifikation, histologisches und zytologisches Grading sowie Regressionsgrading des Prostatakarzinoms.Urologe [A],24, 156 (1985).

    CAS  Google Scholar 

  25. Henry, J. M., Isaacs, J. T.: Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy.J. Urol., 139, 1119 (1988).

    PubMed  CAS  Google Scholar 

  26. Hudson, M. A., Bahnson, R. R., Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer.J. Urol., 142, 1011 (1989).

    PubMed  CAS  Google Scholar 

  27. Imai, K., Suzuki, T., Kobayashi, M., Yamahaka, Y., Tomaru, Y., Sato, J.: The significance of erythrocyte sedimentation rate as a prognostic factor for patients with prostate cancer.Jpn. J. Cancer Res., 81, 971 (1990).

    PubMed  CAS  Google Scholar 

  28. Jurinde, C. D., Pixberg, H. U., Gasser, A., Klippel, K.-F.: Prostate-specific antigen in prostatic carcinoma.Urol. Int., 45, 153 (1990).

    Article  Google Scholar 

  29. Jensen, O. M., Esteve, J.: Cancer in the European Community and its member states.Eur. J. Cancer, 26, 1167 (1990).

    Article  PubMed  CAS  Google Scholar 

  30. Johansson, J. E., Andersson, S.-O.: Prognostic factors in progression free survival and correlated survival in patients with advanced prostatic cancer: Results from a randomized study comprising 150 patients treated with orchiectomy or estrogens.J. Urol., 146, 1327 (1991).

    PubMed  CAS  Google Scholar 

  31. Kumamoto, Y., Tsukamoto, T., Umerhara, T., Shimazaki, J.: Multivariate analyses of prognostic factors in patients with prostatic carcinoma given endocrine therapy.Hinykiko-Kiyo, 36, 275 (1990).

    CAS  Google Scholar 

  32. Meyer, J. S., Sufrin, G., Martin, S. A.: Proliferative activity of benign human prostate, prostatc adenocarcinoma and seminal vesicles evaluated by thymidine labeling.J. Urol., 128, 1353 (1982).

    PubMed  CAS  Google Scholar 

  33. Mostofi, F. K.: Problems of grading carcinoma of the prostate.Sem. Oncol., 3, 161 (1976).

    CAS  Google Scholar 

  34. Mostofi, F. K., Sesterhenn, L. H.: International Histological Classification of Tumors, No. 22, WHO, Geneva 1980.

    Google Scholar 

  35. Mulders, P. F., Dijkman, G. A., Fernandes-del-Maal, P., Theenwes, A. G., Debruyne, F. M.: Analysis of prostatic factors in disseminated prostatic cancer. An update— Dutch Southeastern Urological Cooperative Group.Cancer, 65, 2758 (1990).

    Article  PubMed  CAS  Google Scholar 

  36. Newmann, K. D., Tucker, J. A., Ruenes, A., Walther, P. J.: DNA ploidy heterogeneity grade (pure Gleason 3/3) prostate carcinoma: A problem for routine clinical application of flow cytometric ploidy analysis.J. Urol., 145, 252A (1991).

    Google Scholar 

  37. Ritchie, A. W., Dorey, F., Langfield, L. J., Hannah, J., Lovrekonich, H., deKernion, J. B.: Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of prostate.Br. J. Urol., 62, 245 (1988).

    PubMed  CAS  Google Scholar 

  38. Sandhu, D. P. S., Mayor, P., Sambrook, P., George, J. R.: Increased survival of patients with massive lymphadenopathy and prostate cancer: Evidence of heterogeneous tumor behaviour.Br. J. Urol., 66, 415 (1990).

    PubMed  CAS  Google Scholar 

  39. Schröder, F. H.: Grading of prostate cancer. III: Multivariate analysis of prognostic parameters.The Prostate, 7, 13 (1985).

    Article  Google Scholar 

  40. Schubert, J., Gorski, J.: Zum biologischen Verhalten des Prostatakarzinoms. II. Mitteilung: Klinisch-operative Studien zur lymphogenen Metastasierung des Prostatakarzinoms.Urologe [A],22, 356 (1983).

    Google Scholar 

  41. Stamey, T. A.: Prostatakarzinom. Klinische und morphologische Grundlagen.Urologe [A],30, 348 (1991).

    CAS  Google Scholar 

  42. Stamey, T. A., Kabalin, J. E., McNeal, J. E., Johnstove, F. F., Redwine, E. A., Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.J. Urol., 141, 1076 (1989).

    PubMed  CAS  Google Scholar 

  43. Stamey, T. A.: Die Rolle des prostataspezifischen Antigens bei der Diagnose und Behandlung des Prostatakarzinoms.Urologe [A],29, 52 (1990).

    CAS  Google Scholar 

  44. Studer, U. E., Altwein, J., Bartsch, G.: Aspekte zu den möglichen hormonellen Therapien des Prostatakarzinoms.Urologe [A],30, 310 (1991).

    CAS  Google Scholar 

  45. de Voogt, H. J., Sucin, S., Sylvester, R.: Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from 2 European organizations for research on treatment of cancer trials.J. Urol., 141, 883 (1989).

    PubMed  Google Scholar 

  46. Voges, G. E., McNeal, J. E., Stamey, T. A.: Das inzidentelle Prostatakarzinomvolumen, Lokalisation und Differenzierungsgrad des Tumors im radikalen Prostatektomiepräparat und Stellenwert der Subklassifikation in ein Stadium A1 und A2.Urologe [A],30, 401 (1991).

    CAS  Google Scholar 

  47. Winkler, H., Zinke, H.: Stage D1 prostatic adenocarcinoma: Significance of nuclear DNA ploidy pattern studied by flow cytometry.Mayo Clin. Proc., 63, 103 (1988).

    PubMed  CAS  Google Scholar 

  48. Wittwer, C. J., Hernandez, A. D., Hammond, E. H., Avent, J. M., Greenwood, J.: Tumor ploidy as a predictive factor in patients with localized prostate cancer.J. Urol., 145, 315A (1991).

    Google Scholar 

  49. Wirth, M. P., Müller, H. A., Mauseck, A., Müller, J., Frohmüller, H. G. W.: Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy.Eur. Urol., 20/3, 248 (1991).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology and Outpatient Clinic, Friedrich-Schiller University, Jena, Germany

    J. Schubert & S. Kowalik

Authors
  1. J. Schubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Kowalik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schubert, J., Kowalik, S. The value of prognostic factors in prostatic cancer. International Urology and Nephrology 26, 541–547 (1994). https://doi.org/10.1007/BF02767656

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02767656

Keywords

Search

Navigation